Open the website of any premium probiotic brand. The number is always there: "24 strains." "25 strains." "50 strains." Bigger numbers, bigger claims, bigger promises. The implicit logic is straightforward — more strains in one capsule must mean more benefit. It seems like common sense. But in 2018, a research group in Israel published a paper in Cell that suggests the common sense is exactly backwards.
The strain count race
Spend an hour on the websites of the most-marketed probiotic brands in Europe and the United States and you'll find a strange consistency. The number of strains in the formula is almost always the first or second piece of information presented. Often it's the headline. The numbers escalate year on year — five strains, then ten, then sixteen, then twenty-four. It is a marketing arms race with biology as the casualty.
The numbers vary, but the rhetorical structure does not. The strain count is positioned as a proxy for quality — more strains, more coverage, more chance of doing something useful. The implied promise is that the consumer is buying breadth, and breadth is buying outcomes.
This logic feels intuitive. It is also unsupported by the science of how the gut actually works. The intuition borrows from a model of the gut as an empty vessel — a stomach-shaped jar that you fill with whatever bacteria you choose. That is not the gut. The gut is a competitive ecosystem with finite real estate, an existing population, and rules of its own.
How bacteria actually establish in your gut
When you swallow a probiotic capsule, the bacteria inside it do not enter empty space. They enter a colon already inhabited by something on the order of one hundred trillion microbial cells, organised into hundreds of species and thousands of strains, with a long history of competing for every available niche.1 To survive — and to have any biological effect — the newcomer strain has to do several specific things. It has to survive stomach acid and bile. It has to find a niche that isn't already saturated. It has to attach to the mucosal layer of the colon. And it has to grow faster than the existing population can crowd it out.
The mucosal layer is the actual surface of your colon — the thin, glycoprotein-rich film that lines the inside of the gut wall. It is where most of the biologically relevant microbiome lives. It is also, in surface-area terms, finite. A new bacterium that cannot find a free patch of mucosa to bind to, or cannot displace whatever is already there, simply passes through and exits with the rest of your stool. From the gut's perspective, it never arrived.
The rate at which any given probiotic strain colonises is influenced by four things: the genetics of the strain itself, the composition of the existing microbiome it encounters, the host's diet (because diet feeds the existing community), and — critically — what other strains arrive at the same time. The last point is the one the supplement industry would rather you didn't think about.
The Zmora study: what happens when you actually look
In 2018, a team led by Dr Niv Zmora and Professor Eran Elinav at the Weizmann Institute of Science in Israel did something that, in retrospect, seems obvious — and that almost no probiotic company had bothered to do. They gave a group of healthy adults a high-quality, eleven-strain probiotic supplement, daily, for four weeks. Then, instead of relying on stool samples — which only tell you what is leaving the gut, not what is establishing inside it — they performed direct endoscopic biopsies. They cut tiny samples from the actual mucosal lining of the small and large intestine, and they sequenced them to see which strains had made it home.1
The result was a quiet earthquake.
Roughly half of the subjects showed strong colonisation across most or all of the probiotic strains. The team called these "permissive" microbiomes. The other half showed almost nothing. The probiotic strains had been ingested daily for four weeks, in commercial-grade doses, and they had effectively passed through. These were the "resistant" microbiomes. The difference between the two groups was not the dose, the formulation, or the brand. It was the composition of the existing microbiome the strains had encountered when they arrived.
This was the first finding. The second was, if anything, more uncomfortable for the industry. Among the permissive subjects — the ones where colonisation was working at all — the colonisation rates of the individual strains were noticeably lower than what had been measured in earlier studies using those same strains delivered singly. When the strains were given together, they interfered with each other. The space, the substrate, the attachment sites — all of these were finite, and the eleven strains were now competing for them not just with the host's native flora, but with each other.1
The Zmora paper concluded — in carefully scientific language — that the one-size-fits-all approach to multi-strain probiotics was scientifically untenable. Strain delivery, they argued, should be more individualised, and more thoughtful about what was being given at once.
The companion paper: when more is actively worse
In the same issue of Cell, the same research group published a second paper, this time led by Dr Jotham Suez. The scenario was different. Subjects were given a course of antibiotics — a treatment that depletes the native gut microbiome significantly. Then they were assigned to one of three recovery strategies. One group received the same standard eleven-strain probiotic cocktail. One group received an autologous faecal microbiota transplant — that is, their own stool, collected before the antibiotics, transplanted back into the gut. The third group received nothing, and was left to recover spontaneously.2
The result, again, was the opposite of what the supplement industry would have predicted.
The autologous-FMT group recovered fastest, with their pre-antibiotic microbiome composition restored within days. The do-nothing group recovered second-fastest, with native bacteria gradually re-establishing dominance over a matter of weeks. The probiotic group recovered slowest. Their native microbiome reconstitution was actively impaired by the probiotic supplement. The probiotic strains — by occupying mucosal real estate that would otherwise have been recolonised by the host's own bacteria — held back recovery for as long as six months in some subjects.2
In this scenario, "more bacteria" was worse than "no bacteria." The probiotic was not nothing. It was a competitor.
What this actually means for consumers
It is important to be clear about what these findings do and do not show. They do not show that multi-strain probiotics are useless. There is good evidence — including from earlier work by Tannock and colleagues3 — that specific strains, in specific contexts, can produce measurable benefits in the gut and beyond. What the Zmora and Suez papers show is more specific: the marketing logic of "more strains equals better" is incomplete, and in some conditions actively wrong.
The findings also show something that the supplement industry has been slow to acknowledge: individual response varies enormously. The same product, in the same dose, given to two genetically similar adults living in the same city, can colonise robustly in one and not at all in the other. There is no formulation in the current European or American consumer market that meaningfully accounts for this. They all assume one capsule fits everyone.
The implication for product design is not "stop making multi-strain probiotics." The implication is to think harder about how strains are delivered. Some of the design choices that follow from taking the Zmora and Suez findings seriously include:
- Sequencing strain delivery, rather than packing all strains into a single daily capsule. Different cohorts of strains get different windows in which to attempt colonisation.
- Personalising strain selection to the host microbiome — choosing which strains to deliver based on which strains the host's existing flora is most likely to accept.
- Spacing cohorts of strains across weeks or months, so an early cohort has time to establish before a later one arrives and starts competing.
- Combining strains with selective substrates — prebiotics that preferentially feed the strains being delivered — to give them a competitive advantage during the colonisation window. This is the formal definition of a "synbiotic," as set out by the International Scientific Association for Probiotics and Prebiotics in 2020.4
None of these design choices are radical. They follow straightforwardly from the biology. They are simply not how the current generation of consumer probiotics is built.
The Tiny Tribes response
This is where Tiny Tribes' approach diverges from the strain-count race — and it is the place we are most careful not to overclaim.
The Tiny Tribes protocol delivers twenty-four unique strains in total, but those strains are not packed into a single daily capsule. They are delivered across four phases. Each phase contains ten to twelve strains, with strategic overlaps for continuity between phases. Each phase runs for roughly ninety days, which gives the strains in that phase a real window — measured in weeks, not hours — to attempt colonisation before the next cohort arrives. Each phase is paired with a specific blend of prebiotic substrates chosen to favour the strains being delivered in that window. This is a synbiotic design in the ISAPP sense4 — not a probiotic and a prebiotic in the same capsule, but a coordinated pairing where the prebiotic is chosen for the strains it favours.
In the Intelligence tier of Tiny Tribes, this is layered with microbiome testing — sequencing the host's existing flora to understand which phases, and which emphases within those phases, are most likely to actually take hold. The Zmora paper described "permissive" and "resistant" microbiomes as a phenomenon. We treat it as a design input.
This is not a "fewer strains" approach. It is the same number of strains the better consumer probiotics already offer. What changes is how those strains are sequenced and supported. We believe the science of the gut suggests this is a more grounded approach to multi-strain delivery than packing everything into a single daily dose. We do not yet have evidence that it is superior in outcomes — that is exactly the question our 240-participant clinical study with Maastricht University is designed to answer rigorously. Until that study reads out, what we are claiming is design intent, not proven superiority. We think that distinction matters.
How to evaluate strain claims as a consumer
If you take nothing else from this article, take this: the strain count on a probiotic bottle is a marketing number, not a quality signal. There are formulations with two strains that are excellent products, and formulations with twenty-five strains that are essentially expensive faeces.
When evaluating a probiotic, look for:
- Named strains with specific identifiers. Not "Lactobacillus" — that is a genus, like saying "tree." Look for the full strain name and number, like Lactobacillus rhamnosus GG or Bifidobacterium longum BB536. The strain identifier is what links the product to the clinical research.
- Disclosure of CFU per strain, not just the total. A product claiming fifty billion CFU across twenty-five strains may contain two billion of each, or it may contain forty-nine billion of one and tiny doses of the rest. You should know which.
- Specific clinical research on those specific strains. Strain-level research, not genus-level handwaving. A product that cannot point you to studies on its actual strains is selling you optimism.
- A coherent rationale for the strain combination. If the only reason for a product's twenty-five strains is "more is better," that is not a rationale.5
Be sceptical of proprietary blends without strain disclosure, marketing that emphasises strain count without strain identity, claims that fail to acknowledge individual variation in response, and any product whose evidence base is testimonials rather than trials. None of these things are necessarily disqualifying — but they are warning flags that the company is hoping you will be impressed before you ask the second question.
The gut is not a vessel you can fill with bacteria. It is an ecosystem with its own rules. The supplement industry has spent two decades pretending otherwise — selling capsule counts and strain counts and CFU counts as if biology were arithmetic. The science is finally pushing back, and the products we will see over the next decade will reflect that more than the ones that came before. Tiny Tribes is one bet on that direction. There will be others. The point is to take the biology seriously.
References
- Zmora N. et al. (2018). Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell, 174(6), 1388–1405. https://doi.org/10.1016/j.cell.2018.08.041
- Suez J. et al. (2018). Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell, 174(6), 1406–1423. https://doi.org/10.1016/j.cell.2018.08.047
- Tannock GW. et al. (2000). Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Applied and Environmental Microbiology, 66(6), 2578–2588. https://doi.org/10.1128/AEM.66.6.2578-2588.2000
- Swanson KS. et al. (2020). The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nature Reviews Gastroenterology & Hepatology, 17(11), 687–701. https://doi.org/10.1038/s41575-020-0344-2
- Sniffen JC. et al. (2018). Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One, 13(12), e0209205. https://doi.org/10.1371/journal.pone.0209205